Ratings Traws Pharma, Inc.

Equities

TRAW

US68232V8019

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-29 pm EDT			5-day change	1st Jan Change
0.64 ^USD	+3.11%		-4.62%	-14.16%

Apr. 04	North American Morning Briefing : Focus Turns to -2-	DJ
Apr. 04	Traws Pharma, Inc. Announces Chief Executive Office Changes	CI

Strengths

For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analyst opinion has improved significantly over the past four months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
TRAWS PHARMA, INC.	-14.16%	13.09M	-
IQVIA HOLDINGS INC.	+1.77%	42.75B	B
LONZA GROUP AG	+47.70%	41.61B	A
MODERNA, INC.	+12.24%	41.34B	B-
CELLTRION, INC.	-8.83%	26.59B	C
ICON PUBLIC LIMITED COMPANY	+7.44%	25.49B	B-
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.12B	B
MEDPACE HOLDINGS, INC.	+30.56%	12.24B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.76B	C+
UNITED THERAPEUTICS CORPORATION	+8.35%	11B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes